Atopic dermatitis: an expanding therapeutic pipeline for a complex disease

Thomas Bieber
DOI: https://doi.org/10.1038/s41573-021-00266-6
IF: 112.288
2021-08-20
Nature Reviews Drug Discovery
Abstract:Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains challenging to treat owing to the limited response to available therapies. However, recent advances in understanding of disease mechanisms have led to the discovery of novel potential therapeutic targets and drug candidates. In addition to regulatory approval for the IL-4Ra inhibitor dupilumab, the anti-IL-13 inhibitor tralokinumab and the JAK1/2 inhibitor baricitinib in Europe, there are now more than 70 new compounds in development. This Review assesses the various strategies and novel agents currently being investigated for AD and highlights the potential for a precision medicine approach to enable prevention and more effective long-term control of this complex disease.
pharmacology & pharmacy,biotechnology & applied microbiology
What problem does this paper attempt to address?